SMARCB1 and central nervous system cancer: ATRX loss is frequently used to diagnose gliomas, loss of H3K27me3 is employed to identify specific subtypes of diffuse midline gliomas, and INI1 loss is characteristic of atypical teratoid/rhabdoid tumors.